Spyre Therapeutics, Inc. - 8-K Filing
Spyre Therapeutics announced topline results from the rheumatoid arthritis sub-study of its Phase 2 SKYWAY trial evaluating SPY072; both doses showed statistically significant benefits compared to placebo but did not meet internal criteria for monotherapy prioritization in RA. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $SYRE